抗人肺癌单克隆抗体WL3C9的制备鉴定及血清学诊断意义

本文报道了应用杂交瘤枝术建立的一株新的抗肺癌单克隆抗体(WL3C9)细胞系,并对其分泌的McAb WL3C9及抗体识别的抗原Ag3C9进行了初步鉴定和分析。免疫组化显示,WL3C9与绝大多数肺癌组织(32/40),部分肺外肿瘤(7/18)呈中等或强阳性反应,与绝大多数正常组织不反应,个别呈弱阳性反应。血清ELISA结合抑制试验显示,WL3C9抗体与正常人血清结合抑制率为12％±17％,Ag3C9均为阴性;非肿瘤组血清Ag3C9阳性率为14％(5/35);肺外肿瘤组阳性率为39％(5/13);肺癌组阳性率达80％(36/40);同时测定血清CEA可使肺癌总阳性率提高到90％。研究结果表明,McAb3C9识别的Ag3C9抗原与肺癌密切相关,且具有较高的敏感性和特异性,是一种新的、有希望的肺癌血清学肿瘤标志物,它与CEA有一定互补性,二者联合检测可提高肺癌的检出率。

Preparation and Characterization of Monoclonal Antibody WL3C9 and its Application in Serodiagnosis of Lung Cancer

A novel monoclonal antibody, WL3C9 to human lung carcinoma was reported in this paper. Immunohistochemical study showed that WL3C9 reacted with the vast majority of tested paraffin-embedded tissues of pulmonary carcinoma and various kinds of other tumor tissues as well as a small number of some normal tissues, such as bron- chiolar epithelium and liver. Immunoblotting indicated that WL3C9 can recognize an antigen designated Ag3C9 which has a molecular weight of 30 kD. The antibody can also be used to detect Ag3C9 antigen in sera of patients with lung carcinoma by inhibition assay. The results showed that higher level of inhibition was noted in sera from 80% of patients with lung carcinoma, 39% of patients with non-pulmonary carcinoma and 14% of patients with benign diseases as compared with sera from healthy adults. Measurement of CEA of the same panel of sera revealed that the level of Ag3C9 and CEA was not parallel in sera and demonstrated that Ag3C9 and CEA were different antigens. The aforementioned results suggest that monoclonal antibody WL3C9 was promising in clinical management of human lung carcinoma.